← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 640.7% to $7.7M, while Net income decreased 55.9% to ($465.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $7.7MWatch
- Profitability — Net income ($465.3M)Watch
- Cash generation — Free cash flow ($383.7M)Note
- Accounting — Formula-grey distress score · manipulation and earnings-quality screens not computedNote
- Insiders — 0 buys; 16 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Crinetics Pharmaceuticals, Inc.: We may require substantial additional financing to achieve our goals, and failure to obtain this necessary capital when needed on acceptable terms, or at all, could lead us to delay, limit, reduce, abandon or terminate our product development programs, commercialization efforts or other operations.
Where the revenue comes from
Fiscal 2025, as Crinetics Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$5.4M
- Collaboration and license revenue$2.3M
- License$1.8M
Leadership changes
From Crinetics Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Jeff Knight · departureeff. 2026-04-10
- Jeff Knight · Directors · departureeff. 2026-03-17
- Dana Pizzuti · departureeff. 2025-12-31
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Crinetics Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.